Trials / Unknown
UnknownNCT01317186
The Role of FGF23 and Asymmetric Dimethylarginine (ADMA) in Chronic Kidney Disease
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 100 (estimated)
- Sponsor
- Ankara Education and Research Hospital · Other Government
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
In chronic kidney disease calcium (Ca) and phosphate (P) metabolism disorders are very common and also they are one of the leading causes of morbidity in these population. FGF23 is a novel factor that contributes Ca-P disorders. It has been hypothesized that FGF 23 increase is mediated by asymmetric dimethylarginine (ADMA). The aim of the study is to evaluate this hypothesis.
Conditions
Timeline
- Start date
- 2011-03-01
- First posted
- 2011-03-17
- Last updated
- 2011-03-17
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT01317186. Inclusion in this directory is not an endorsement.